Rui Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rui Xie has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Jingyu Xu
Collaborative Innovation Center for Tissue Repair and Regenerative Medicine, Zunyi Medical University, Zunyi, Guizhou 563006, P.R. China
30 shared publications Qian Du
Department of Endoscopy and Digestive System, Guizhou Provincial People's Hospital, No. 83, Zhongshan East Road, Guiyang, Guizhou 550002, PR China
24 shared publicationsYanxia Hu
Collaborative Innovation Center for Tissue Repair and Regenerative Medicine, Zunyi Medical University, Zunyi, Guizhou 563006, P.R. China
14 shared publicationsTing Zhang
Collaborative Innovation Center for Tissue Repair and Regenerative Medicine, Zunyi Medical University, Zunyi, Guizhou 563006, P.R. China
11 shared publicationsXiaoxu Yang
Department of Gastroenterology, Digestive Disease Hospital Affiliated Hospital of Zunyi Medical University Zunyi China
11 shared publicationsJun Lou
Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, China
10 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (4) , 1-17
Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review)
Inflammatory bowel disease (IBD) is a group of chronic, relapsing and systemic inflammatory disorders primarily affecting the gastrointestinal tract, including Crohn's disease, ulcerative colitis and rarer distinct subtypes such as indeterminate colitis. IBD has shown a marked shift in global epidemiology, with increasing incidence in newly industrialized regions across Africa, Asia and Latin America. The pathogenesis of IBD reflects a complex interplay between genetic susceptibility, mucosal immune dysregulation, intestinal barrier dysfunction, microbial dysbiosis and environmental exposures. Clinically, conventional therapy, including 5‑aminosalicylic acid, corticosteroids and conventional immunosuppressants, is limited by incomplete efficacy and safety concerns. Alternative therapeutic strategies included biological agents (anti‑tumor necrosis factor α, anti‑integrin, anti‑IL‑12/23 and anti‑tumor necrosis factor‑like ligand 1A), small‑molecule inhibitors (JAK inhibitors, tyrosine kinase 2 inhibitors, sphingosine‑1‑phosphate receptor modulators and NLRP3 inhibitors), microbiome‑based interventions (fecal microbiota transplantation, probiotics and engineered microbes) and regenerative approaches (mesenchymal stem cells and intestinal organoids). The present review aimed to summarize mechanistic insights and clinical evidence for established and emerging therapies and discusses current challenges and future directions for individualized, disease‑modifying treatment of IBD.
- 18 August 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (4) , 1-17
Open AccessInflammatory bowel disease treatment: Mechanisms to clinical translation (Review)
Inflammatory bowel disease (IBD) is a group of chronic, relapsing and systemic inflammatory disorders primarily affecting the gastrointestinal tract, including Crohn's disease, ulcerative colitis and rarer distinct subtypes such as indeterminate colitis. IBD has shown a marked shift in global epidemiology, with increasing incidence in newly industrialized regions across Africa, Asia and Latin America. The pathogenesis of IBD reflects a complex interplay between genetic susceptibility, mucosal immune dysregulation, intestinal barrier dysfunction, microbial dysbiosis and environmental exposures. Clinically, conventional therapy, including 5‑aminosalicylic acid, corticosteroids and conventional immunosuppressants, is limited by incomplete efficacy and safety concerns. Alternative therapeutic strategies included biological agents (anti‑tumor necrosis factor α, anti‑integrin, anti‑IL‑12/23 and anti‑tumor necrosis factor‑like ligand 1A), small‑molecule inhibitors (JAK inhibitors, tyrosine kinase 2 inhibitors, sphingosine‑1‑phosphate receptor modulators and NLRP3 inhibitors), microbiome‑based interventions (fecal microbiota transplantation, probiotics and engineered microbes) and regenerative approaches (mesenchymal stem cells and intestinal organoids). The present review aimed to summarize mechanistic insights and clinical evidence for established and emerging therapies and discusses current challenges and future directions for individualized, disease‑modifying treatment of IBD.
- 22 July 2026
- Published by Elsevier in Cellular Signalling
- Vol. 147, 112753
Multi-omics and artificial intelligence nominate PCLAF as a prognostic and druggable target for hepatitis B virus-associated hepatocellular carcinoma
- 22 July 2026
- Published by Elsevier in Cellular Signalling
- Vol. 147, 112753
Multi-omics and artificial intelligence nominate PCLAF as a prognostic and druggable target for hepatitis B virus-associated hepatocellular carcinoma
- 17 April 2026
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
Risk factors and predictive model for transjugular intrahepatic portosystemic shunt dysfunction in cirrhotic patients
Background: Transjugular intrahepatic portosystemic shunt (TIPS) has been widely adopted for the management of decompensated portal hypertension in cirrhotic patients. However, TIPS dysfunction remains a critical clinical challenge. This study aimed to identify risk factors for TIPS dysfunction and develop a predictive model to assess this complication. Methods: A retrospective study was conducted involving cirrhotic patients who underwent TIPS between 2017 and 2024. Among 1052 initially screened patients, 676 were finally included in the analysis. TIPS dysfunction was diagnosed using ultrasound and angiographic evaluations. The dataset was randomly divided into a training set and a validation set at a ratio of 7 : 3. A stepwise logistic regression analysis was performed in the training set to establish a predictive model. Ten-fold cross-validation was used for internal validation, and the validation set was applied for external validation. The predictive discrimination was evaluated using the receiver operating characteristic curve, and the calibration curve was used to assess the consistency. Shapley Additive Explanations analysis was conducted to interpret the model. Results: Independent risk factors for TIPS dysfunction included age, main portal vein thrombosis, platelets, D value, angle β, and the angle between the selected hepatic vein and inferior vena cava. The model showed good predictive performance with an area under the curve of 0.896 (sensitivity 0.804, specificity 0.844, and accuracy 93.2%) for training set and 0.905 (sensitivity 0.870, specificity 0.826, and accuracy 86.5%) for validation set. The calibration curve from the 10-fold cross-validation in the training set also showed good agreement between prediction and observation. Shapley Additive Explanations analysis showed that Beta value is the most important feature affecting prediction, and allows the estimation of the specific risk of TIPS dysfunction for each individual in the model. Conclusion: This study developed a valid predictive model for assessing risk factors for TIPS dysfunction in cirrhotic patients. Recognition of these risk factors and optimized TIPS shunt management may contribute to improved outcomes in patients undergoing TIPS procedures.
- 17 April 2026
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
Risk factors and predictive model for transjugular intrahepatic portosystemic shunt dysfunction in cirrhotic patients
Background: Transjugular intrahepatic portosystemic shunt (TIPS) has been widely adopted for the management of decompensated portal hypertension in cirrhotic patients. However, TIPS dysfunction remains a critical clinical challenge. This study aimed to identify risk factors for TIPS dysfunction and develop a predictive model to assess this complication. Methods: A retrospective study was conducted involving cirrhotic patients who underwent TIPS between 2017 and 2024. Among 1052 initially screened patients, 676 were finally included in the analysis. TIPS dysfunction was diagnosed using ultrasound and angiographic evaluations. The dataset was randomly divided into a training set and a validation set at a ratio of 7 : 3. A stepwise logistic regression analysis was performed in the training set to establish a predictive model. Ten-fold cross-validation was used for internal validation, and the validation set was applied for external validation. The predictive discrimination was evaluated using the receiver operating characteristic curve, and the calibration curve was used to assess the consistency. Shapley Additive Explanations analysis was conducted to interpret the model. Results: Independent risk factors for TIPS dysfunction included age, main portal vein thrombosis, platelets, D value, angle β, and the angle between the selected hepatic vein and inferior vena cava. The model showed good predictive performance with an area under the curve of 0.896 (sensitivity 0.804, specificity 0.844, and accuracy 93.2%) for training set and 0.905 (sensitivity 0.870, specificity 0.826, and accuracy 86.5%) for validation set. The calibration curve from the 10-fold cross-validation in the training set also showed good agreement between prediction and observation. Shapley Additive Explanations analysis showed that Beta value is the most important feature affecting prediction, and allows the estimation of the specific risk of TIPS dysfunction for each individual in the model. Conclusion: This study developed a valid predictive model for assessing risk factors for TIPS dysfunction in cirrhotic patients. Recognition of these risk factors and optimized TIPS shunt management may contribute to improved outcomes in patients undergoing TIPS procedures.
- Open Access
- 31 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
The central regulator HIF-1α in digestive system pathologies: inflammation and cancer
Hypoxia-inducible factor-1α (HIF-1α) is a critical transcriptional regulator that allows cells to detect and respond to hypoxic conditions. Its stabilized expression and prolonged activation significantly contribute to the development and progression of inflammatory diseases and malignancies within the digestive system. In the context of inflammation, HIF-1α plays a pivotal role in the pathogenesis of various disorders—including periodontitis, eosinophilic esophagitis, viral hepatitis, pancreatitis, and inflammatory bowel disease—by modulating the expression of inflammatory mediators, driving cellular metabolic reprogramming, and influencing tissue barrier function. In terms of tumor biology, this review synthesizes pan-cancer analysis data to summarize the expression patterns of HIF-1α in major gastrointestinal malignancies, including esophageal, gastric, pancreatic, hepatocellular, and colorectal cancers. It elucidates HIF-1α’s role in directly promoting tumor cell proliferation, invasion, and drug resistance, while also remodeling the tumor microenvironment to regulate immune responses. We dissect how HIF-1α cooperatively drives the formation of an immunosuppressive microenvironment, thereby influencing the efficacy of immunotherapy. This review aims to integrate the regulatory networks and molecular mechanisms of HIF-1α in digestive system inflammation, tumors, and their immune microenvironment, ultimately providing novel theoretical foundations and strategic insights for targeted therapies and immune interventions in related diseases.
- 31 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Open AccessThe central regulator HIF-1α in digestive system pathologies: inflammation and cancer
Hypoxia-inducible factor-1α (HIF-1α) is a critical transcriptional regulator that allows cells to detect and respond to hypoxic conditions. Its stabilized expression and prolonged activation significantly contribute to the development and progression of inflammatory diseases and malignancies within the digestive system. In the context of inflammation, HIF-1α plays a pivotal role in the pathogenesis of various disorders—including periodontitis, eosinophilic esophagitis, viral hepatitis, pancreatitis, and inflammatory bowel disease—by modulating the expression of inflammatory mediators, driving cellular metabolic reprogramming, and influencing tissue barrier function. In terms of tumor biology, this review synthesizes pan-cancer analysis data to summarize the expression patterns of HIF-1α in major gastrointestinal malignancies, including esophageal, gastric, pancreatic, hepatocellular, and colorectal cancers. It elucidates HIF-1α’s role in directly promoting tumor cell proliferation, invasion, and drug resistance, while also remodeling the tumor microenvironment to regulate immune responses. We dissect how HIF-1α cooperatively drives the formation of an immunosuppressive microenvironment, thereby influencing the efficacy of immunotherapy. This review aims to integrate the regulatory networks and molecular mechanisms of HIF-1α in digestive system inflammation, tumors, and their immune microenvironment, ultimately providing novel theoretical foundations and strategic insights for targeted therapies and immune interventions in related diseases.
- Open Access
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Helicobacter pylori–induced PPFIA4 orchestrates immune network–promoting gastritis and gastric bacterial colonization
Bacteria-modulated gastric epithelial cells (GECs) play key roles in Helicobacter pylori –associated pathology. Here, we demonstrate both procolonization and proinflammation roles of GEC-derived PPFIA4 in H . pylori infection. PPFIA4 was elevated in GECs from gastric mucosa of H . pylori –infected patients and mice. PPFIA4 could be synergistically induced by H . pylori and IL-33 via the CagA/AP1 pathway. Human gastric PPFIA4 correlated with H . pylori colonization and the severity of gastritis, and H . pylori colonization and inflammation were attenuated in Ppfia4 ΔGEC mice. Mechanistically, PPFIA4’s SAM1 domain bound domains from CaMK to the first L27 of CASK and subsequently formed a PPFIA4/CASK/AKT1 complex to activate AKT1, resulting in NF-κB activation and MMP1/CXCL3 secretion. This not only led to decreased E-cadherin and ZO-1 by MMP1, thereby promoting gastric mucosal damage to foster H . pylori colonization, but also resulted in increased gastric influx of G-MDSCs via CXCL3-dependent migration, thereby promoting gastritis and impairing H . pylori –specific IFN-γ–producing CD4 + T cell responses to foster H . pylori colonization. Furthermore, we identified a PPFIA4 inhibitor, kira6, which effectively inhibited GEC’s MMP1/CXCL3 production and ameliorated gastric H . pylori colonization and gastritis. Overall, PPFIA4 could be a promising therapeutic target, as it collectively ensures H . pylori persistence and promotes gastritis.
- 5 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (9)
Open AccessHelicobacter pylori–induced PPFIA4 orchestrates immune network–promoting gastritis and gastric bacterial colonization
Bacteria-modulated gastric epithelial cells (GECs) play key roles in Helicobacter pylori –associated pathology. Here, we demonstrate both procolonization and proinflammation roles of GEC-derived PPFIA4 in H . pylori infection. PPFIA4 was elevated in GECs from gastric mucosa of H . pylori –infected patients and mice. PPFIA4 could be synergistically induced by H . pylori and IL-33 via the CagA/AP1 pathway. Human gastric PPFIA4 correlated with H . pylori colonization and the severity of gastritis, and H . pylori colonization and inflammation were attenuated in Ppfia4 ΔGEC mice. Mechanistically, PPFIA4’s SAM1 domain bound domains from CaMK to the first L27 of CASK and subsequently formed a PPFIA4/CASK/AKT1 complex to activate AKT1, resulting in NF-κB activation and MMP1/CXCL3 secretion. This not only led to decreased E-cadherin and ZO-1 by MMP1, thereby promoting gastric mucosal damage to foster H . pylori colonization, but also resulted in increased gastric influx of G-MDSCs via CXCL3-dependent migration, thereby promoting gastritis and impairing H . pylori –specific IFN-γ–producing CD4 + T cell responses to foster H . pylori colonization. Furthermore, we identified a PPFIA4 inhibitor, kira6, which effectively inhibited GEC’s MMP1/CXCL3 production and ameliorated gastric H . pylori colonization and gastritis. Overall, PPFIA4 could be a promising therapeutic target, as it collectively ensures H . pylori persistence and promotes gastritis.
- Open Access
- 9 February 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (4) , 1-15
Helicobacter pylori and hyperglycemia fuel gastric cancer glycolysis: Mechanisms and targeted intervention (Review)
Helicobacter pylori (H. pylori) is a Gram‑negative bacterial pathogen, and infection with this pathogen is a primary risk factor for gastric cancer (GC), often inducing chronic gastritis, which further increases the risk of cancer. Glycolysis carries out a key role in GC metabolism, serving as the primary energy pathway for cancer cells, particularly under hypoxic conditions. Enhanced glycolysis allows GC cells to sustain high proliferation rates and produce lactic acid, creating an acidic tumor microenvironment that promotes tumor progression. Understanding the mechanisms of H. pylori‑driven glycolysis may provide new insights into GC pathogenesis and reveal novel therapeutic targets. The present review addresses advances in glycolysis research in GC, summarizing its characteristics, identifying key mediators involved in metabolic reprogramming and exploring potential molecular mechanisms to recommend new targets for therapy.
- 9 February 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 57 (4) , 1-15
Open AccessHelicobacter pylori and hyperglycemia fuel gastric cancer glycolysis: Mechanisms and targeted intervention (Review)
Helicobacter pylori (H. pylori) is a Gram‑negative bacterial pathogen, and infection with this pathogen is a primary risk factor for gastric cancer (GC), often inducing chronic gastritis, which further increases the risk of cancer. Glycolysis carries out a key role in GC metabolism, serving as the primary energy pathway for cancer cells, particularly under hypoxic conditions. Enhanced glycolysis allows GC cells to sustain high proliferation rates and produce lactic acid, creating an acidic tumor microenvironment that promotes tumor progression. Understanding the mechanisms of H. pylori‑driven glycolysis may provide new insights into GC pathogenesis and reveal novel therapeutic targets. The present review addresses advances in glycolysis research in GC, summarizing its characteristics, identifying key mediators involved in metabolic reprogramming and exploring potential molecular mechanisms to recommend new targets for therapy.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 4059-4072
Rapamycin and Chloroquine Modulate Insulin Resistance and Hepatic Steatosis in a High-Fat/High-Cholesterol Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease Mouse Model
Objective: To establish a short-term high-fat/high-cholesterol (HFHC) diet-induced Metabolic dysfunction-associated steatotic liver disease (MASLD) mouse model, and evaluate the effects of rapamycin (RaPa) and chloroquine (CQ) on this model to explore their therapeutic potential and side effects. Methods: An early MASLD mouse model was constructed via short-term HFHC diet feeding. Model mice were intraperitoneally injected with RaPa or CQ. Drug effects were analyzed on body weight, liver weight, lipid metabolism-related genes (APOB, FASN, PLIN2), inflammatory factors (IL-6, IL-10), and fibrosis markers (LOX, Col-1α-1, CCL2, TGFβ1, PDGFRβ, α-SMA) at mRNA and protein levels. Results: RaPa ameliorated body weight and liver weight in early MASLD mice, downregulated FASN and PLIN2 expression, upregulated IL-10 mRNA levels, and alleviated hepatic steatosis, but induced metabolic disorders such as Insulin resistance and hyperlipidemia. In contrast, CQ promoted FASN and PLIN2 expression, exacerbated hepatic steatosis, reduced IL-10 mRNA levels, and upregulated fibrosis-related markers (LOX, TGFβ1, PDGFRβ, α-SMA) at both mRNA and protein levels, thereby driving MASLD progression to liver fibrosis. Notably, CQ improved metabolic abnormalities in model mice, including obesity, hyperlipidemia, and Insulin resistance. Conclusion: RaPa and CQ exhibit dual effects on early MASLD: RaPa alleviates hepatic steatosis but exacerbates metabolic disorders, whereas CQ improves metabolic abnormalities but accelerates liver fibrosis. This paradox highlights the need to balance metabolic regulation and liver injury prevention in MASLD treatment, providing critical experimental insights for targeted drug development.
- 1 November 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 4059-4072
Open AccessRapamycin and Chloroquine Modulate Insulin Resistance and Hepatic Steatosis in a High-Fat/High-Cholesterol Diet-Induced Metabolic Dysfunction-Associated Steatotic Liver Disease Mouse Model
Objective: To establish a short-term high-fat/high-cholesterol (HFHC) diet-induced Metabolic dysfunction-associated steatotic liver disease (MASLD) mouse model, and evaluate the effects of rapamycin (RaPa) and chloroquine (CQ) on this model to explore their therapeutic potential and side effects. Methods: An early MASLD mouse model was constructed via short-term HFHC diet feeding. Model mice were intraperitoneally injected with RaPa or CQ. Drug effects were analyzed on body weight, liver weight, lipid metabolism-related genes (APOB, FASN, PLIN2), inflammatory factors (IL-6, IL-10), and fibrosis markers (LOX, Col-1α-1, CCL2, TGFβ1, PDGFRβ, α-SMA) at mRNA and protein levels. Results: RaPa ameliorated body weight and liver weight in early MASLD mice, downregulated FASN and PLIN2 expression, upregulated IL-10 mRNA levels, and alleviated hepatic steatosis, but induced metabolic disorders such as Insulin resistance and hyperlipidemia. In contrast, CQ promoted FASN and PLIN2 expression, exacerbated hepatic steatosis, reduced IL-10 mRNA levels, and upregulated fibrosis-related markers (LOX, TGFβ1, PDGFRβ, α-SMA) at both mRNA and protein levels, thereby driving MASLD progression to liver fibrosis. Notably, CQ improved metabolic abnormalities in model mice, including obesity, hyperlipidemia, and Insulin resistance. Conclusion: RaPa and CQ exhibit dual effects on early MASLD: RaPa alleviates hepatic steatosis but exacerbates metabolic disorders, whereas CQ improves metabolic abnormalities but accelerates liver fibrosis. This paradox highlights the need to balance metabolic regulation and liver injury prevention in MASLD treatment, providing critical experimental insights for targeted drug development.
- Open Access
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1593727
The immunoregulatory role of helper T cells in Helicobacter pylori infection
Helicobacter pylori (H. pylori) is a pathogenic bacterium that can survive in the human gastric mucosa and cause chronic infections. More than half of the global population is affected by H. pylori infection, which is closely associated with the development of gastritis, gastric ulcers, gastric cancer, and mucosa - associated lymphoid tissue lymphoma. The immune response triggered by H. pylori infection is complex and involves multiple immune cells. Among them, helper T cells (Th cells) play a crucial role in regulating the immune response. In recent years, researchers have conducted in - depth explorations of the immunoregulatory mechanisms, pathological effects of Th cells in H. pylori infection, and their applications in treatment. However, there are still problems such as insufficient understanding of the functions of Th cell subsets and unclear clinical treatment strategies. This paper aims to review the immunoregulatory role of Th cells in H. pylori infection, analyze their mechanism of action in the pathological process, and explore the future research directions and the development of treatment strategies, providing a theoretical basis for research in this field.
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1593727
Open AccessThe immunoregulatory role of helper T cells in Helicobacter pylori infection
Helicobacter pylori (H. pylori) is a pathogenic bacterium that can survive in the human gastric mucosa and cause chronic infections. More than half of the global population is affected by H. pylori infection, which is closely associated with the development of gastritis, gastric ulcers, gastric cancer, and mucosa - associated lymphoid tissue lymphoma. The immune response triggered by H. pylori infection is complex and involves multiple immune cells. Among them, helper T cells (Th cells) play a crucial role in regulating the immune response. In recent years, researchers have conducted in - depth explorations of the immunoregulatory mechanisms, pathological effects of Th cells in H. pylori infection, and their applications in treatment. However, there are still problems such as insufficient understanding of the functions of Th cell subsets and unclear clinical treatment strategies. This paper aims to review the immunoregulatory role of Th cells in H. pylori infection, analyze their mechanism of action in the pathological process, and explore the future research directions and the development of treatment strategies, providing a theoretical basis for research in this field.
- Open Access
- 19 February 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (4) , e70330
The Use of Gut Organoids: To Study the Physiology and Disease of the Gut Microbiota
The intestinal flora has attracted much attention in recent years. An imbalance in the intestinal flora can cause not only intestinal diseases but also cause a variety of parenteral diseases, such as endocrine diseases, nervous system diseases and cardiovascular diseases. Research on the mechanism of disease is likely to be hampered by sample accessibility, ethical issues, and differences between cellular animal and physiological studies. However, advances in stem cell culture have made it possible to reproduce 3D human tissues in vitro that mimic the cellular, anatomical and functional characteristics of real organs. Recent studies have shown that organoids can be used to simulate the development and disease of the gut and intestinal flora and have a wide range of applications in intestinal flora physiology and disease. Intestinal organoids provide a preeminent in vitro model system for cultivating microbiota that influence GI physiology, as well as for understanding how they encounter intestinal epithelial cells and cause disease. The mechanistic details obtained from such modelling may provide new avenues for the prevention and treatment of many gastrointestinal (GI) disorders. Researchers are now starting to take inspiration from other fields, such as bioengineering, and the rise of interdisciplinary approaches, including organoid chip technology and microfluidics, has greatly accelerated the development of organoids to generate intestinal organoids that are more physiologically relevant and suitable for gut microbiota studies. Here, we describe the development of organoid models of gut biology and the application of organoids to study the pathophysiology of diseases caused by intestinal dysbiosis.
- 19 February 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (4) , e70330
Open AccessThe Use of Gut Organoids: To Study the Physiology and Disease of the Gut Microbiota
The intestinal flora has attracted much attention in recent years. An imbalance in the intestinal flora can cause not only intestinal diseases but also cause a variety of parenteral diseases, such as endocrine diseases, nervous system diseases and cardiovascular diseases. Research on the mechanism of disease is likely to be hampered by sample accessibility, ethical issues, and differences between cellular animal and physiological studies. However, advances in stem cell culture have made it possible to reproduce 3D human tissues in vitro that mimic the cellular, anatomical and functional characteristics of real organs. Recent studies have shown that organoids can be used to simulate the development and disease of the gut and intestinal flora and have a wide range of applications in intestinal flora physiology and disease. Intestinal organoids provide a preeminent in vitro model system for cultivating microbiota that influence GI physiology, as well as for understanding how they encounter intestinal epithelial cells and cause disease. The mechanistic details obtained from such modelling may provide new avenues for the prevention and treatment of many gastrointestinal (GI) disorders. Researchers are now starting to take inspiration from other fields, such as bioengineering, and the rise of interdisciplinary approaches, including organoid chip technology and microfluidics, has greatly accelerated the development of organoids to generate intestinal organoids that are more physiologically relevant and suitable for gut microbiota studies. Here, we describe the development of organoid models of gut biology and the application of organoids to study the pathophysiology of diseases caused by intestinal dysbiosis.
- Open Access
- 15 January 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-12
Mast cells: key players in digestive system tumors and their interactions with immune cells
Mast cells (MCs) are critical components of both innate and adaptive immune processes. They play a significant role in protecting human health and in the pathophysiology of various illnesses, including allergies, cardiovascular diseases and autoimmune diseases. Recent studies in tumor-related research have demonstrated that mast cells exert a substantial influence on tumor cell behavior and the tumor microenvironment, exhibiting both pro- and anti-tumor effects. Specifically, mast cells not only secrete mediators related to pro-tumor function such as trypsin-like enzymes, chymotrypsin, vascular endothelial cell growth factor and histamine, but also mediators related to anti-tumor progression such as cystatin C and IL-17F. This dual role of mast cells renders them an under-recognized but very promising target for tumor immunotherapy. Digestive system tumors, characterized by high morbidity and associated mortality rates globally, are increasingly recognized as a significant healthcare burden. This paper examines the influence of mast cell-derived mediators on the development of tumors in the digestive system. It also explores the prognostic significance of mast cells in patients with various gastrointestinal cancers at different stages of the disease. Additionally, the article investigates the interactions between mast cells and immune cells, as well as the potential relationships among intratumoral bacteria, immune cells, and mast cell within digestive system microenvironment. The aim is to propose new strategies for the immunotherapy of digestive system tumors by targeting mast cells.
- 15 January 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-12
Open AccessMast cells: key players in digestive system tumors and their interactions with immune cells
Mast cells (MCs) are critical components of both innate and adaptive immune processes. They play a significant role in protecting human health and in the pathophysiology of various illnesses, including allergies, cardiovascular diseases and autoimmune diseases. Recent studies in tumor-related research have demonstrated that mast cells exert a substantial influence on tumor cell behavior and the tumor microenvironment, exhibiting both pro- and anti-tumor effects. Specifically, mast cells not only secrete mediators related to pro-tumor function such as trypsin-like enzymes, chymotrypsin, vascular endothelial cell growth factor and histamine, but also mediators related to anti-tumor progression such as cystatin C and IL-17F. This dual role of mast cells renders them an under-recognized but very promising target for tumor immunotherapy. Digestive system tumors, characterized by high morbidity and associated mortality rates globally, are increasingly recognized as a significant healthcare burden. This paper examines the influence of mast cell-derived mediators on the development of tumors in the digestive system. It also explores the prognostic significance of mast cells in patients with various gastrointestinal cancers at different stages of the disease. Additionally, the article investigates the interactions between mast cells and immune cells, as well as the potential relationships among intratumoral bacteria, immune cells, and mast cell within digestive system microenvironment. The aim is to propose new strategies for the immunotherapy of digestive system tumors by targeting mast cells.